ArticleFrontiers in systems biology2026
Glioma identification from microRNA biomarkers using machine learning.
Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most aggressive malignant brain tumours, occurring mostly in adults and accounting for approximately 80% of central nervous system malignant tumours. Traditional diagnostic methods are both invasive and expensive, thus accurate, minimally invasive, and cost-effective early detection is vital to guide personalised treatment plans. MicroRNAs (miRNAs) are stable non-coding RNAs detectable in various body fluids (e.g., serum, plasma, and cerebrospinal Fluid (CSF)) that regulate gene expression and influence cellular processes; their dysregulation is a significant factor in cancer development. This makes them a promising biomarker for glioma classification. In this article, we present a glioma identification methodology from miRNA data using machine learning (ML) followed by data analysis for miRNA biomarker investigation. A machine learning pipeline is applied to classify glioma from controls as well as from meningioma samples using miRNA expression data obtained by four Gene Expression Omnibus (GEO) datasets (GSE112264, GSE113486, GSE113740, GSE139031). After preprocessing, five feature selection techniques (LASSO, mRMR, ReliefF, RFE, and RF importance) were employed. Six machine learning algorithms (LR, KNN, DT, RF, SVM, XGB) were used for classification with and without SMOTE oversampling. Performance was assessed after 5-fold cross-validation, in terms of accuracy, F1-score, precision, recall, and area under the curve (AUC). The results showed that in binary classification (glioma vs controls) all models achieving up to 100% accuracy, and in multi-class classification (glioma vs meningioma vs controls) up to 100% F1-score was achieved with both KNN and XGB classifiers. The top-ranked miRNAs were also analysed and compared with biomarkers previously known from the literature. Seven miRNAs were identified as potential biomarkers, namely the miR-125a-3p, miR-4276, miR-4648, miR-4763-3p, miR-663a, miR-6784-5p and miR-873-3p, and were independently validated on the GSE211692 dataset.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.